Inhibrx Biosciences (INBX) Net Income towards Common Stockholders (2023 - 2025)
Inhibrx Biosciences (INBX) reported Net Income towards Common Stockholders of -$32.8 million for Q4 2025, up 31.4% year-over-year from -$25.0 million in Q4 2024, and up 6.87% quarter-over-quarter from -$35.3 million in Q3 2025.
Inhibrx Biosciences (INBX) Net Income towards Common Stockholders (2023 - 2025) Analysis & Trends
Inhibrx Biosciences (INBX) has 3 years of Net Income towards Common Stockholders data on file, last reported at -$32.8 million in Q4 2025.
- Net Income towards Common Stockholders for Q4 2025 came in at -$32.8 million, up 31.4% year-over-year; the trailing twelve-month figure through Dec 2025 was -$140.1 million (down 108.3% YoY), and the FY2025 annual result was -$140.1 million, down 108.3% from the prior year.
- Net Income towards Common Stockholders improved to -$32.8 million in Q4 2025 per INBX's latest filing, from -$35.3 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $1.9 billion in Q2 2024 and troughed at -$92.0 million in Q4 2023.
- A 3-year average of $123.3 million and a median of -$43.9 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders soared 4048.85% in 2024, then plunged 101.54% in 2025.
- A 3-year view of Net Income towards Common Stockholders shows it stood at -$92.0 million in 2023, then surged by 47.96% to -$47.9 million in 2024, then soared by 31.4% to -$32.8 million in 2025.
- Business Quant data shows INBX's Net Income towards Common Stockholders at -$32.8 million in Q4 2025, -$35.3 million in Q3 2025, and -$28.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Inhibrx Biosciences | 186.16 Mn | 186.16 Mn | - | -32.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -32.83 Mn |
| Sep 30, 2025 | -35.26 Mn |
| Jun 30, 2025 | -28.65 Mn |
| Mar 31, 2025 | -43.31 Mn |
| Dec 31, 2024 | -47.87 Mn |
| Sep 30, 2024 | -43.86 Mn |
| Jun 30, 2024 | 1.86 Bn |
| Mar 31, 2024 | -78.71 Mn |
| Dec 31, 2023 | -91.97 Mn |
| Sep 30, 2023 | -51.79 Mn |
| Jun 30, 2023 | -47.05 Mn |